

CURRICULUM VITAE

**Alan Christy Hunter B.Sc. (Hons), D.Phil., F.R.Pharm.S., F.R.S.C., C.Chem.,
F.H.E.A.**

Mobile: 07718088695

E-mail address: chunter@lincoln.ac.uk

Academic Qualifications

University of Sussex D.Phil. (Bioorganic Chemistry)	1997
University of Brighton B.Sc. (Hons) Class 2.1 (Pharmacy)	1992

Professional Qualifications

Fellow of the Higher Education Academy (F.H.E.A.)	2016
Fellow of the Royal Society of Chemistry (F.R.S.C.)	2013
Fellow of the Royal Pharmaceutical Society (F.R.Pharm.S.)	2013
G.Ph.C. Registered (number 2041352)	2011
Chartered Chemist (C.Chem.)	2002
Member of the Royal Society of Chemistry (M.R.S.C.)	2002
Member of the Royal Pharmaceutical Society (M.R.Pharm.S.)	1992

Employment & Professional Experience

Associate Professor in Pharmaceutics Lincoln School of Pharmacy, University of Lincoln	02/09/2019-Present
Reader in Pharmaceutical Sciences Leicester School of Pharmacy, De Montfort University.	01/04/2018-01/09/2019
Senior Lecturer in Pharmaceutics Leicester School of Pharmacy, De Montfort University.	05/12/2016 - 31/03/2018
Senior lecturer in Pharmaceutical Nanoscience School of Pharmacy, University of Manchester.	01/07/2012 – 31/10/2016
Senior Lecturer in Pharmaceutics School of Pharmacy, University of Brighton	01/09/2000 - 06/06/2012
Lecturer in Pharmaceutics School of Pharmacy, University of Brighton	02/11/1998 - 01/09/2000

EPSRC funded Post Doctoral Research Fellow (Biomaterials) School of Pharmacy, University of Brighton	16/03/1998 - 01/11/1998
Retail Pharmacy Manager National Cooperative Chemists, Peacehaven	11/08/1997 - 13/03/1998
Locum Community Pharmacist	02/08/1993 – Present
Pre-registration & Basic Grade Pharmacist Southlands Hospital, Shoreham-by-Sea	01/08/1992 - 30/09/1993

Teaching and research roles and responsibilities Leicester Pharmacy School (12/2016-Present):

⇒ Teaching experience:

PHCO1301- Compounding
 PHAR1604-Fundamentals of Medicine Design
 PHAR1701-Preparing for Practice 1
 PHAR1702-People and Medicines 1
 PHAR1703-People and Medicines 2
 PHCO2307-Product development
 PHCO2312-Chemical Analysis, Quality and Stability
 PHAR2604-Medicine Development and Manufacture
 PHCO3302-Quality Assurance and Quality by design Principles
 PHCO3311-Development and Manufacture of Pharmaceutical Products
 PHAR3604- Drug Discovery and Delivery
 PHCO3313-New Approaches to Drug Delivery
 PHAR4602-Project (Module Leader)
 PHAR5310-Biopharmaceuticals and Molecular Toxicology

- ⇒ Widening participation lead
- ⇒ School outreach lead
- ⇒ Fitness To Practice Investigator
- ⇒ Science in to practice integration

⇒ Continuation of research in Advanced Drug Delivery, Nanomedicine and Biocatalysis

Teaching roles and responsibilities Manchester Pharmacy School (2012-2016):

- ⇒ Modernization of Pharmaceutics to provide a course fit for the 21st Century. This included re-modelling of year 2 pharmaceutics lectures, practical classes, designing and having built a brand new wet lab. Writing justifications for internal bids (608K) as well as purchasing and installation of all new equipment.
- ⇒ Accreditation of MPharm course with focus on sections for Pharmaceutics and School Staff.
- ⇒ Widening participation with Year 0 pharmaceutics introduction for 6th Form college students. Lecturing to schools 'A day in the life of an academic pharmacist'

- ⇒ Year 2 Lectures in Pharmaceutical Technology as well as practical's and formulation case studies. 4th Year lectures in Advanced Drug Delivery and Nanomedicine. Development of this 4th year module with area speciality of nanomedicine in cancer
- ⇒ School Chemical Safety Officer.
- ⇒ Lead in Pharmaceutical Sciences for integration of science in to practice on MPharm
- ⇒ Unit Leader for integrated research skills unit.
- ⇒ Senior Internal Examiner (Pharmaceutics).

New Areas of Research initiated Manchester Pharmacy School (2012-2016):

- ⇒ Drug targeting to Placenta and Foetus using cubosomes and peptides (PhD student completing September)
- ⇒ Development of transdermal nanoformulations for treatment of Raynaud's phenomenon and Calcinosis
- ⇒ Development of solid oral dosage forms based on Self Nano Emulsifying Drug Delivery Systems (SNEDDS)
- ⇒ Pharmacological activity of pharmaceutical polymers on smooth muscle
- ⇒ Differential regulation of the protein disulphide isomerases by estrogenic compounds as novel breast cancer treatments

Teaching roles and responsibilities School of Pharmacy, University of Brighton, (1998-2012):

- ⇒ Enabled students to understand and appreciate the theory and practice of pharmaceutical sciences and to develop professional awareness, relevance and skills appropriate to their level. These include workshops, case studies, interpretive assignments and presentations to facilitate understanding and encourage development of cognitive and transferable skills.
- ⇒ Incorporated latest research materials into teaching. Have written Royal Pharmaceutical Society of Great Britain accredited lectures in areas of pharmaceutical technology, physical pharmacy, biopharmacy and molecular pharmaceutics, advanced drug delivery systems and bioorganic chemistry. Designed 9 accredited laboratory protocols, exercises and experiments for undergraduates (levels 2-4) in physical pharmacy related to medicine production, formulation, advanced drug delivery and bioorganic chemistry and supervised these laboratory sessions. Delivered lectures, seminars and tutorials to undergraduate and post graduate students (Postgraduate Diploma in Industrial Pharmacy, Post Graduate Diploma for Overseas Pharmacy students).
- ⇒ Have actively encouraged research among the undergraduate students. They have achieved multiple publications in internationally recognised peer reviewed journals from final year projects.
- ⇒ Master classes in spectroscopy for 6th form students.

Administrative roles, School of Pharmacy, University of Brighton, UK (1998-2012):

- ⇒ Joint head then head of pharmaceuticals division. Responsible for maintaining the academic standards and efficient running of accredited pharmaceuticals modules (physical pharmacy, pharmaceutical technology, biopharmacy, drug formulation design, and advanced drug delivery systems) and in pharmaceutical sciences bioorganic chemistry in relation to drug design and metabolism.
- ⇒ Module leader in Physical pharmacy in relation to medicine production, pharmaceutical technology (M.Pharm. and PCS) and bioorganic chemistry. Role in module design and content, implementation, delivery and assessment [approved and accredited by the Royal Pharmaceutical Society of Great Britain (5 yrs)].
- ⇒ Member of both the University and School ethics committee. Responsible for assessment of projects involving human subjects and tissues for biological research and clinical trials within the University and the joint Sussex/Brighton medical School.
- ⇒ Role in allocating non-staff financial resources to the pharmaceuticals section as approved by the school management group.
- ⇒ Presented strategies for directing and planning, and for the implementation of policy decisions within the School and the University.
- ⇒ Responsible for assessing and attaining essential equipment for the undergraduate pharmaceuticals laboratory.
- ⇒ Member of Pharmacy Examination and Examiners Board (Master of Pharmacy, Bachelor of Pharmaceutical and Chemical Sciences).
- ⇒ Member of Pharmacy Thesis Panel with responsibilities in student welfare and academic standards
- ⇒ Internal PhD examiner.
- ⇒ Role in acquisition of accurate mass spectral analyser, ion trap and upgrading of NMR facility (SHRIF bids).

Other Appointments

- ⇒ Director of Engagement, School of Pharmacy, University of Lincoln (2020)
- ⇒ Review Editor, Editorial Board of Nanobiotechnology (specialty section of Frontiers in Bioengineering and Biotechnology, Frontiers in Molecular Biosciences and Frontiers in Materials) (2020)
- ⇒ Reviewer Medical Research Council, UK. (2020)
- ⇒ Nanomedicine MSc development group Cadiz University (2020)
- ⇒ Management Committee for COST Action on Cancer Nanomedicines (2018-2023)
- ⇒ Reviewer Israel Science Foundation Joint NSFC-ISF research Grant (2017)
- ⇒ Grant dispute resolver Fundação para a Ciência e a Tecnologia, I.P. (FCT), Portugal (2017)
- ⇒ Visiting Professor in Nanomedicine (Drug Delivery), University of Cadiz, (2017)
- ⇒ External PhD examiner, University of Copenhagen, Denmark (2016)
- ⇒ Expert assessor for FWF Sitria Spitzer Austrian Science Application Fund (2015)
- ⇒ Expert assessor for Netherlands Organisation for Scientific Research (NOW), Division for Chemical Sciences (CW)(2015)
- ⇒ Expert assessor for Welsh Government, National Institute for Social Care and Health Research (NISCHR) (2014)
- ⇒ External DSc examiner, Aarhus University, Denmark (2014)
- ⇒ Internal PhD examiner, University of Manchester, UK. (2014)
- ⇒ External PhD examiner, University of Copenhagen, Denmark (2014)
- ⇒ External PhD examiner, University of the West Indies, St Augustine, Trinidad (2013)

- ⇒ External PhD examiner, University of Nottingham, UK (2013)
- ⇒ Grant reviewer for Medical Research Council (MRC) (2011)
- ⇒ Visiting Professor in Advanced Drug Delivery, University of Cadiz (2009, 2010)
- ⇒ Expert assessor in Nanomedicine to Kentucky Science and Engineering Foundation (2010)
- ⇒ External MPhil examiner, University of the West Indies, St Augustine, Trinidad (2009)
- ⇒ Expert reviewer for Danish Agency for Science, Technology and Innovation (2008)
- ⇒ External PhD examiner, University of Cadiz, Spain (2007)
- ⇒ Expert assessor to the Portuguese Government Department of Science (2005)
- ⇒ GSK Consultant (1998)

Research Profile and Interests

My research interests lie at the multidisciplinary interface of pharmacy, chemistry and pharmaceutical sciences particularly in the areas of improved drug safety (Intravenous nanomedicines, Gene Therapy) by mechanism, molecular pharmaceutics, site-specific targeting, drug probe design for metabolism and ion channels.

Advanced Drug Delivery:

⇒ Gene therapy with cationic vectors and the direct effect of the vector on cellular function (e.g. initiation of apoptosis, regulation of gene transcription etc.). Recent work from this laboratory has identified for the first time that cationic macromolecules can initiate mitochondrially mediated apoptotic programme differently, a process which depends on macromolecular size and structure of the vector. For instance some cationic polymers (e.g. PEI) can induce pore formation across the outer mitochondrial membrane leading to the release of cytochrome C and subsequent activation of Caspases 9 and 3. Whereas others (e.g. low molecular weight poly(L-lysine) induce Cytochrome C release from mitochondria following activation of protein kinases and phospholipases. Current work is focussing on the understanding of the molecular basis of pore formation as well as direct effects of polycations on gene transcription (particularly endogenous house keeping genes) using DNA microarray chips.

⇒ Understanding of the molecular basis of non-IgE based hypersensitivity reaction to intravenously injected pharmaceutical colloids and nanomedicines (e.g. therapeutic polymers, liposomes, advanced functional nanoparticles such as carbon nanotubes. Recent work in collaboration with the US Army has demonstrated a role for complement activation in initiation of hypersensitivity following infusion of colloidal and polymeric medicines. This programme investigates the molecular basis of complement activation particularly by stealth long-circulating entities. Understanding of these events is critical for future development of safer drug delivery systems and pharmaceutical colloids for parenteral administration.

Pharmaceutical technology:

⇒ This includes design of novel controlled release tablets as a strategy for lifecycle management of effective drugs that have lost their patent protection. This programme pays particular attention to the site of drug absorption in the GI tract and biological factors that play vital roles in drug bioavailability (i.e. P-glycoprotein).

Drug probe design for metabolic and ion channel studies:

⇒ To date no fungal cytochrome P-450 X-ray structures exist due in part to the membrane bound nature of these enzymes. Using developed in house synthetic strategies we have shown all four possible binding orientations via hydroxylation of a single steroidal molecule for the first time and shown that single functional groups can radically alter metabolic fate. Furthermore in this hydroxylase, binding orientation is not dictated by terminal polar functionality but determined by ring structure. Numerous novel metabolites have been isolated and characterized from these studies with novel activity and use in control of membrane fluidity in liposomes to generate long circulating particulate entities.

⇒ Recently demonstrated the first example of steroidal ring-A lactonization by a fungal biocatalytic source. Furthermore ongoing studies have for the first time achieved biocatalytic 8 β -hydroxylation on a range of steroidal nuclei.

⇒ As a 'synthetic spin-off' I have been involved in a number of studies into ion channel pharmacology focussing on membrane impermeant antioestrogen of tamoxifen. This has demonstrated sole activation of smooth muscle BK channels from the extracellular side. Further studies have involved deconstruction of the tamoxifen side-chain and the effect of side chain substituted oestrones on BK channels.

Research Grants and Management

- ⇒ 2020 ITN H2020 DIRNANO Grant £303,000 (PI)
- ⇒ 2019 Scottish Innovation Grant £40,000 (PI)
- ⇒ 2015 Undergraduate equipment bid £10,000 awarded
- ⇒ 2015 Biomedical Research Unit development funding £25 K (Co-I)
- ⇒ 2014-2016 3 externally funded international PhD studentships £237,000 (PI)
- ⇒ 2014 Raynaud's and Scleroderma Association Grant £111,268 awarded (Co-I)
- ⇒ 2014 CIC Confidence in Concept MRC Grant £88,847 awarded (Co-I)
- ⇒ 2014 Internal equipment bid 416K awarded (Principle author)
- ⇒ 2013 Internal equipment bid 182K awarded (Principle author)

- ⇒ Trained and advised staff and students on research strategies. Identified necessary personnel and resources. Promoted intellectual development and encouraged individual abilities through independent research and investigative work. Monitored research programmes through regular formal review meetings.
- ⇒ Raised and obtained internal and external research funds (approx 4 million pounds to date): support has been afforded by University of Brighton (1998-2000), EPSRC case award (1999-2001), GSK (2000-2002), US Army (2003-2006), Overseas studentships (2001-2007) and Danish Council for Strategic Research (2008-2013).
- ⇒ Successfully involved in the supervision of 8 PhD students, over 40 undergraduate final year project students to completion. Currently supervising 2 PhD students and 1 Post Doctoral Fellow
- ⇒ Initiated and managed national and international collaborative research programmes. Current active collaborators include Prof. S. M. Moghimi (University of Copenhagen, Denmark), Dr. G. M. Dick (University of Western Virginia, USA), Prof. A. Szewczyk (Nencki Institute, Poland), Prof. J. Szebeni (Semmler University, Hungary), Dr. G. D. Rees (GSK, UK), Dr. M. C. Allen (University of Brighton, UK).

- ⇒ Founder member of Molecular Targeting and Polymer Toxicology Group with Prof. S.M. Moghimi (1999).

Research Publications and Editorial Activities

Publications:

- ⇒ Publications: research papers and critical reviews (72), editorials (21), meeting reports (4), refereed abstracts (11), Total: 106 publications-list appended
- ⇒ Published work has received 12,191 citations (as of November 2020, source: Google Scholar).
- ⇒ First paper published 1997; h-index: 37 (37 papers with at least 33 citations each): m-index>1.5; 16 papers/reviews with more than 100 citations each.

Editorial and scientific advisory boards:

- ⇒ Associate Editor, Journal of nanotheranostics 2020-Present
- ⇒ Editorial board Frontiers Nanobiotechnology 2020-Present
- ⇒ Associate Editor of Current Bionanotechnology 2015-2018
- ⇒ Editorial board member Current Drug Delivery Technologies 2013-2018
- ⇒ Top Reviewer for Nanomedicine: Nanotechnology, Biology and Medicine 2011, 2012, 2013 and 2014.
- ⇒ Theme editor – Advanced Drug Delivery Reviews (2011). Complement monitoring of nanomedicines and implants.
- ⇒ Advisory board member - Medical Science Monitor (2004) International Scientific Literature
- ⇒ Editorial board member - Drug Discovery Today (2002 - 2004) Elsevier
- ⇒ Monitor editor - Pharmaceutical Science and Technology Today (1999-2000) Elsevier

Reviewing activities:

- ⇒ Invited reviewer for: Acta Biomaterialia; Advanced Drug Delivery Reviews; African Journal of Biotechnology; Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids; Biomacromolecules; Biomaterials; Cancer Letters; Collection of Czechoslovak Chemical Communications, Current Drug Delivery; Current Drug Delivery Journal; Current Drug Discovery Technologies; Current Organic Chemistry; Drug Discovery Today; European Journal of Lipid Science and Technology; Expert Opinion on Drug Delivery International Journal of Molecular Sciences; International Journal of

Nanomedicine; International Journal of Pharmaceutics; Journal of Biomaterials Applications; Journal of Bioorganic and Medicinal Chemistry, Journal of Biomedical Materials Research Part A; Journal of Biomedical Nanotechnology; Journal of Controlled Release; Journal of Drug Delivery; Journal of Enzyme Inhibition and Medicinal Chemistry; Journal of Steroid Biochemistry and Molecular Biology; Journal of Natural Products, Neuroscience letters; Journal of Toxicology, Langmuir; Marine Drugs; Materials Science and Engineering; Medicinal Research Reviews; Methods; Molecular Pharmaceutics; Nanomedicine; Nano Today; Nature Biotechnology; Nature Nanotechnology; Neuroscience letters; Particle and Fibre Toxicology; Pharmaceutical Biology; Pharmaceutical Research; Progress in Polymer Science; RSC Advances; Steroids; Tetrahedron; Toxicological Sciences; Toxicology.

⇒ Text Book Reviewer: Medicinal Chemistry an Introduction (G. Thomas), John Wiley and Sons ISBN 0-471-988073.

Conference Organisation and Invited Lectures

Conference organisation:

- ⇒ Global Education Symposium, Oct 11-12, New York City, New York, USA, 2018
- ⇒ Global Education Symposium, Sept 15-17, New York City, New York, USA, 2016
- ⇒ Co-organiser, the first international application based Quartz Crystal Microbalance Conference (QCM, Brighton UK, 2002)

Invited Speaker:

- ⇒ 2002 University of Kuopio, Finland
- ⇒ 2006 University of the West Indies, Kingston Jamaica
- ⇒ 2007 University of Brighton. UK
- ⇒ 2007 Kocaeli University, Izmit, Turkey
- ⇒ 2007 University of Cadiz, Spain
- ⇒ 2007 World BioPharm Forum, Hammersmith Hospital, London
- ⇒ 2008 Plenary Lecture, University of the West Indies, Kingston Jamaica
- ⇒ 2008 University of Cadiz, Spain
- ⇒ 2010 University of Copenhagen
- ⇒ 2010 2008 University of Cadiz, Spain
- ⇒ 2010 University of Warsaw, Poland
- ⇒ 2013 University of the West Indies, Trinidad, St Augustine, Dept. Chemistry
- ⇒ 2013 The University of Manchester, UK.
- ⇒ 2014 Strathclyde University, UK.
- ⇒ 2014 2013 University of the West Indies, Trinidad, St Augustine, Dept. Medicine
- ⇒ 2014 University of Sussex, UK. Faculty of Life Sciences
- ⇒ 2014 The University of Manchester, St Mary's Hospital, UK
- ⇒ 2015 The University of Manchester University, UK, British Pharmaceutical Students Society
- ⇒ 2017 University of Cadiz, Spain
- ⇒ 2017 De Montfort University, UK

- ⇒ 2018 De Montfort University, UK
- ⇒ 2019 Lincoln University, UK
- ⇒ 2019 Speaker and Chair, New Trends in Nanomedicine, International School of Nanomedicine Erice, Sicily, Italy
- ⇒ 2019 Speaker and Chair, Nanomedicine Summer School, Cadiz University, Spain
- ⇒ 2020 Online MSc Drug Delivery and Nanomedicine, Cadiz University, Spain

Other

American Asthma Foundation ranked in top 5% of authors cited in pharmacology journals in the world (2009, 2010).

Film Credits

West Pier Point and VoliAmo: Hobie Tiger helm, Hobie 16 Crew, Powerboat camera platform driver.

Hobbies

Street Photography (Over 600,000 views on FLICKR)

Dogs!

Captain of departmental lawn bowls team 'The Pharmers'

PUBLICATION LIST

All citations sourced from Google Scholar
(IF = Impact Factor; Cit = Number of Citations; X* = Citation value shared)
Orcid ID (orcid.org/0000-0003-1100-7761)

Google Scholar metrics for 10-11-2020

Citations 12191

h-index 37

i10-Index 60

Mendeley database 200,000 views on work of A. C. Hunter

Publications:

A.C. Hunter, K. J. Hunter S. M. Moghimi, Z. Farhangrazi, Nanomedicine: Scientific training requirements for the future, in *Nanomedicine: Exploring the Potential of*

Nanotherapeutics (Z. S. Farhangrazi, S. M. Moghimi, eds.). CRC Press, Boca Raton. 2020, (in preparation)-Chapter accepted

S. M. Moghimi, L-P. Wu, **A.C. Hunter**, A. Yaghmur, Z. S. Farhangrazi, Nanomedicine Characterization: Gross Morphology, Nanostructural Displays and Size Distribution in *Nanomedicine: Exploring the Potential of Nanotherapeutics* (Z. S. Farhangrazi, S. M. Moghimi, eds.). CRC Press, Boca Raton. 2020, (in preparation)-Chapter accepted

Published papers

2020

Z. S. Farhangrazi, G. Sancini, **A. C. Hunter**, S. M. Moghimi, Airborne particulate matter and SARS-CoV-2 partnership: virus hitchhiking, stabilization and immune cell targeting - A hypothesis, *Frontiers in Immunology*, (Molecular Innate Immunity) In Press (IF = 6.42)

2019

S. M. Moghimi, D. Simberg, T. Skotland, A. Yaghmur, **A. C. Hunter**. The interplay between blood proteins, complement on nanomedicine performance and responses, *The Journal of Pharmacology and Experimental Therapeutics*, (2019) jpet.119.258012;DOI: <https://doi.org/10.1124/jpet.119.258012>. (IF = 3.86)

2017

F. Fei, A. Gallas, Y-C Chang, Y. Rao, **A. C. Hunter**, R. E. P. Winpenny, A. L. Herrick, N. P. Lockyer, C. F. Blanford, Assaying the effectiveness of chelation-based calcinosis treatments using Quartz Crystal Microbalance, *ACS Applied Materials and Interfaces* (2017) Vol. 9, 27544-27552 (IF = 8.09)

P. P. Wibro, A. C. Anselmo, P. Nilsson, R. Urbanics, J. Szebeni, **A. C. Hunter**, S. Mitragotri, T. E. Molines, S. M. Moghimi, By-passing polymeric nano-particle-mediated adverse injection reactions through particle shape control and erythrocyte 'hitch-hiking.' *Nature Nanotechnology* (2017) Vol. 12 pp 589-594 (IF = 38.9, Cit = 51)

A.C. Hunter, Y. I. Oni, J. Rafferty, J. M. Gardiner, M. Uttley, Metabolism of steroidal lactones by the fungus *Corynespora cassicola* CBS 161.60 results in mechanistically unique intramolecular ring-D cyclisation resulting in C-14 spiro-lactones. *Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids* (2017) Vol. 1862, pp 939-945 (IF = 4.9)

A.C. Hunter, S. M. Moghimi, Smart polymers in drug delivery: a biological perspective. *Polymer Chemistry* (2017) Vol. 8, pp 41-51 (IF = 5.3, Cit = 19)

2016

H. Andreson, L. Parhamifar, **A. C. Hunter**, V. Shahi, S. M. Moghimi, AFM Visualization of Sub-50nm polyplex disposition to the nuclear pore complex without compromising nuclear envelope integrity, *Journal of Controlled Release* (2016) Vol. 244, pp 24-29
(IF = 7.8, Cit = 8)

S. M. Moghimi, **A. C. Hunter**, D. Peer, Platelet mimicry: The emperor's new clothes?
Nanomedicine: Nanotechnology, Biology and Medicine (2016) Vol. 12, pp 245-248.
(IF = 5.72, Cit = 8)

2015

A.C. Hunter, S. Patel, C. Dedi, H. T. Dodd, R. A. Bryce, Metabolic fate of 3 α ,5-cycloandrostanes in the endogenous lactonization pathway of *Aspergillus tamaris* KITA.
Phytochemistry (2015) Vol. 119, pp 19-25.
(IF = 3.1, Cit = 2)

2013

I.Hamad, **A. C. Hunter**, S. M. Moghimi, Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL and apolipoproteins A1 and B-100. *Journal of Controlled Release* (2013) Vol. 170, pp 167-174.
(IF = 7.7, Cit = 29)

M. C. Allen, J. Maher, **A. C. Hunter**, J. G. Mabley, J. Lippiat, Smooth muscle relaxation and activation of the large conductance Ca²⁺ activated K⁺ (BKCa) channel by novel oestrogens.
British Journal of Pharmacology (2013) Vol. 169, pp 1153-1165.
(IF = 6.81, Cit = 7)

A.J. Andersen, B. Windschiegl, S. Ilbasimis-Tamer, I. T. Degim, **A. C. Hunter**, T. L. Andresen, S. M. Moghimi, Complement activation by PEG-functionalized multi-walled carbon nanotubes is independent of PEG molecular mass and surface density. *Nanomedicine: Nanotechnology, Biology and Medicine* (2013) Vol. 9, pp 469-473.
(IF = 5.7, Cit = 33)

A.J. Andersen, J. T. Robinson, H. Dai, **A. C. Hunter**, T. L. Andresen, S. M. Moghimi, Single-walled carbon nanotube surface control of complement sensing and activation. *ACS Nano* (2013) Vol. 7, pp 1108-1119.
(IF = 13.7, Cit = 96)

2012

S. M. Moghimi, P. B. Wibroe, S. Helvig, Z. Shadi Farhangrazi, **A. C. Hunter**, Genomic perspectives in inter-individual adverse responses following Nanomedicine administration: the way forward. *Advanced Drug Delivery Reviews*, (2012) Vol. 64, pp 1385-1393.
(IF = 15.6, Cit = 34)

A.C. Hunter, J. E. Elsom, P. P. Wibroe, S. M. Moghimi. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. *Nanomedicine: Nanotechnology, Biology and Medicine* (2012) Vol. 8, pp S5-S20.

(IF = 5.7, Cit = 82*)

A.C. Hunter, J. E. Elsom, P. P. Wibroe, S. M. Moghimi. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. *Maturatis*, (2012) Vol. 73, pp 5-18.

(IF = 2.9, Cit = 82*)

S. M. Moghimi, L. Parhamifar, D. Ahmadvand, P. P. Wibroe, T. L. Andresen, Z. S. Farhangrazi, **A. C. Hunter**, Particulate systems for targeting of macrophages: Basic and therapeutic concepts. *Journal of innate immunity* (2012) Vol. 4, pp 509-528.

(IF = 3.9, Cit = 38)

S. M. Moghimi, **A. C. Hunter**, T. L. Andresen, Factors controlling Nanoparticle pharmacokinetics: An integrated analysis and perspective, *Annual Review of Pharmacology and Toxicology*, (2012) Vol. 52, pp 481-503. (Invited review).

(IF = 13.29, Cit = 333)

A.K. Larsen, D. Malinska, I. Koszela-Piotrowska, L. Parhamifar, **A. C. Hunter**, S. M. Moghimi, Polyethylenimine-mediated impairment of mitochondrial membrane potential, respiration and membrane integrity: Implications for nucleic acid delivery and gene therapy. *Mitochondrion*, (2012) Vol. 12, pp 162-168.

(IF = 3.2, Cit = 35)

B. Lettieri, A. J. Andersen, **A. C. Hunter**, S. M. Moghimi, Complement system and the brain: Selected pathologies and avenues toward engineering of neurological nanomedicines. *Journal of Controlled Release*, (2012) Vol. 161, pp 283-289

(IF = 7.8, Cit = 22)

2011

A.C. Hunter, S-J. Rymer, C. Dedi, H. T. Dodd, Q. C. Nwozor, S. M. Moghimi, Transformation of a range of structurally diverse steroidal analogues by the fungus *Corynespora cassiicola* results in a range of 8 β -monohydroxylated metabolites with evidence in favor of 8 β -hydroxylation through inverted binding in the 9 α -hydroxylase. *Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids* (2011) Vol. 1811, pp 1054-1061.

(IF = 4.9, Cit = 13)

S. M. Moghimi and **A. C. Hunter**, Complement monitoring of nanomedicines and implants, *Advanced Drug Delivery Reviews*, (2011) Vol. 63, pp 963-964.

(IF = 15.6, Cit = 2)

S.M.Moghimi, A. J. Andersen, D. Ahmadvand, P. P. Wibroe, T. L. Andresen, **A. C. Hunter**, Material properties in complement activation. *Advanced Drug Delivery Reviews*, (2011) Vol 63, 1000-1007. (IF = 15.6, Cit = 189)

2010

I. Hamad, O. Al-Hanbali, **A. C. Hunter**, K. J. Rutt, T. L. Andresen, S. M. Moghimi. Distinct polymer architecture switches complement activation pathways at the nanosphere-serum interface: Implications for stealth nanoparticle engineering. *ACS Nano*, (2010) Vol. 4, pp 6629-6638.

(IF = 13.7, Cit = 196)

A.C. Hunter, C. Collins, H. T. Dodd, Cinzia Dedi, S-J. Koussoroplis, Transformation of a series of saturated isomeric steroidal diols by *Aspergillus tamarii* KITA reveals a precise stereochemical requirement for entrance into the lactonization pathway. **Journal of Steroid Biochemistry and Molecular Biology** (2010) Vol. 122, pp 352-358.

(IF = 4.5, Cit = 9)

S. M. Moghimi, A. J. Anderson, S. H. Hashemi, B. Lettiero, D. Ahmadvand, **A. C. Hunter**, T. L. Andresen, I. Hamad, J. Szebeni, Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead. **Journal of Controlled Release** (2010) Vol. 146, pp 175-181.

(IF = 7.8, Cit = 144)

L. Parhamifar, A. K. Larsen, **A. C. Hunter**, T. Andresen, S. M. Moghimi, Polycation cytotoxicity: a delicate matter for nucleic acid therapy-focus of poly(ethyleneimine). **Soft Matter** (2010) Vol. 6, pp 4001-4009.

(IF = 3.8, Cit = 172)

A.C. Hunter and S. M. Moghimi, Cationic carriers of genetic material and cell death: a mitochondrial tale. **Biochimica et Biophysica Acta. Bioenergetics** (2010) Vol. 1797, pp1203-1209.

(IF = 4.2, Cit = 122)

S. M. Moghimi and **A. C. Hunter**, Letter-Complement monitoring of carbon nanotubes. **Nature Nanotechnology** (2010) Vol. 5, p 382.

(IF = 38.9, Cit = 30)

A.C. Hunter, H. Khuenl-Brady, P. Barrett, H. T. Dodd, C. Dedi, Transformation of a series of saturated 3 α -substituted 17-keto and 17 α -oxa-D-homo-steroids by *Aspergillus tamarii* KITA reveals stereochemical restriction of steroid binding orientation in the minor hydroxylation pathway. **Journal of Steroid Biochemistry and Molecular Biology** (2010) Vol. 118, pp 171-176.

(IF = 4.5, Cit = 17)

2009

A.C Hunter, Application of the quartz crystal microbalance to Nanomedicine. **Journal of Biomedical Nanotechnology** (2009) Vol. 6, pp 669-675.

(IF = 4.5, Cit = 25)

A.J. Anderson, S. H. Hashemi, T. L. Andresen, **A. C. Hunter**, S. M. Moghimi Complement: Alive and kicking nanomedicines. **Journal of Biomedical Nanotechnology** (2009) Vol. 5, pp 364-372.

(IF = 5.0, Cit = 67)

A. C. Hunter, K. R. Watts, C. Dedi, H. T. Dodd, An unusual ring-A opening and other steroid transformations catalyzed by the thermophilic fungus *Myceliophthora thermophila*, **Journal of Steroid Biochemistry and Molecular Biology** (2009) Vol. 116, pp 171-177.

(IF = 4.5, Cit = 22)

A. C. Hunter, E. Coyle, F. Morse, C. Dedi, H. T. Dodd, Transformation of 5-ene steroids by the fungus *Aspergillus tamarii* KITA: Mixed molecular fate in lactonization and hydroxylation

pathways with identification of a putative 3 β -hydroxy-steroid dehydrogenase/ Δ^5 - Δ^4 isomerase pathway, ***Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids*** (2009) Vol. 1791, pp 110-117.
(IF = 4.9, Cit = 45)

2008

I. Hamad, **A. C. Hunter**, J. Szebeni, S. M. Moghimi, Poly(ethylene glycol)s trigger complement activation in human serum through alternative and lectin pathways: a plausible cause for anaphylaxis (2008) ***Molecular Immunology*** (2008) Vol. 46, pp 225-232.
(IF = 3.1, Cit = 194)

I. Hamad, **A. C. Hunter**, K. J. Rutt, Z. Liu, H. Dai, S. M. Moghimi, Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q-dependent classical and alternative pathways ***Molecular Immunology*** (2008) Vol. 45, pp 3797-3803.
(IF = 3.1, Cit = 113)

A. C. Hunter, P. W. Mills, C. Dedi, H. T. Dodd, Predominant allylic hydroxylation at carbons 6 and 7 of 4 and 5-ene functionalized steroids by the thermophilic fungus *Rhizomucor Tauricus* IMI23312 ***Journal of Steroid Biochemistry and Molecular Biology*** (2008) Vol. 108, pp 155-163.
(IF = 4.5, Cit = 22)

J. Elsom, M. I. Lethem, G. D. Rees, **A. C. Hunter**, Novel quartz crystal microbalance based biosensor for detection of oral epithelial cell-microparticulate interaction in real-time, ***Biosensors and Bioelectronics*** (2008) Vol.11, pp 1259-1265.
(IF = 8.1, Cit = 33)

2007

R. Mukhopadhyay, O. Al-Hanbali, S. Pillai, A. G. Hemmersam, R. L. Meyer, **A. C. Hunter**, K. J. Rutt, F. Besenbacher, S. M. Moghimi, P. Kingshott. Ordering of binary polymeric nanoparticles on hydrophobic surfaces assembled from low volume fraction dispersions. ***Journal of the American Chemical Society*** (2007) Vol. 129 pp 13390-13391.
(IF = 14.35, Cit = 34)

A. C. Hunter, H. Bergin-Simpson, Distinct metabolic handling of 3 β -hydroxy-17 α -oxa-D-homo-5 α -androstan-17-one by the filamentous fungus *Aspergillus tamaris* KITA: evidence in support of steroid/hydroxylase binding hypothesis. ***Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids*** (2007) Vol. 1771, pp 1254-1261.
(IF = 4.9, Cit = 22)

A. C. Hunter, The current chemical utility of marine and terrestrial filamentous fungi in side-chain chemistry. ***Current Organic Chemistry*** (2007) Vol. 11, pp 665-677 (Invited Review).
(IF = 2.1, Cit = 7)

O. Al-Hanbali, N. M. Onwuzo, K. J. Rutt, C. M. Dadswell, S. M. Moghimi, A. C. Hunter, Modification of the Stewart biphasic colorimetric assay for accurate quantitative determination of Pluronic[®] and Tetronic[®] block copolymers in biological systems. ***Analytical Biochemistry*** (2007) Vol.361, pp 287-293.
(IF = 2.2, Cit = 23)

2006

A. C. Hunter. Molecular hurdles in polyfectin design and mechanistic background to polycation induced toxicity. *Advanced Drug Delivery Reviews* (2006) Vol. 58, pp 1523-1531 (Invited Review). (IF = 15.6, Cit = 405)

S. M. Moghimi, I. Hamad, R. Bünger, T. L. Andresen, K. Jørgensen, **A. C. Hunter**, L. Rosivall, L. Baranji and J. Szebeni. Activation of the Human Complement System by cholesterol-rich and PEGylated liposomes- Modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. *Journal of Liposome Research* (2006) Vol. 16, pp 167-174.
(IF = 1.8, Cit = 46)

O. Al-Hanbali, K. J. Rutt, D. K. Sarker, **A. C. Hunter** and S. M. Moghimi. Concentration dependent structural ordering of Poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. *Journal of Nanoscience and Nanotechnology*. (2006) Vol. 6, pp 3126-3133.
(IF = 1.3, Cit = 53)

A. C. Hunter, J. Elsom, L. Ross and R. Barrett. Ring-B functionalized androst-4-en-3-ones and ring-C substituted pregn-4-en-3-ones undergo differential transformation in *Aspergillus tamaris* KITA: ring-A transformation with all C-6 substituted steroids and ring-D transformation with C-11 substituents. *Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids*. (2006) Vol. 1761, pp 360-366.
(IF = 4.9, Cit = 26)

A. C. Hunter and S-M. Priest. An efficient one-pot synthesis generating 4-ene-3,6-dione functionalised steroids from steroidal 5-en-3 β -ols using a modified Jones oxidation methodology. *Steroids*. (2006) Vol. 71, pp 30-33.
(IF = 2.7, Cit = 32)

2005

P. Symonds, J. C. Murray, **A. C. Hunter**, G. Debska, A. Szewczyk and S. M. Moghimi. Low and High molecular weight poly(L-Lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial mediated apoptosis differently. *FEBS Letters*. (2005) Vol. 579, pp 6191-6198.
(IF = 4.5, Cit = 118)

A. C. Hunter, S. Kennedy, S-J Clabby and J. Elsom. Fate of novel *Quasi* reverse steroidal substrates by *Aspergillus tamaris* KITA: bypass of lactonisation and an exclusive role for the minor hydroxylation pathway. *Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids*. (2005) Vol. 1734, pp 190-197.
(IF = 4.9, Cit = 16)

*S. M. Moghimi, P. Symonds, J. C. Murray, **A. C. Hunter**, G. Debska, and A. Szewczyk. A two-stage poly(ethylenimine)-mediated cytotoxicity: Implications for gene-transfer/therapy. *Molecular Therapy* (2005) Vol. 11, pp 990-995.
(IF = 7.0, Cit = 892)

S. M. Moghimi, **A. C. Hunter** and J. C. Murray. Nanomedicine: Current status and future prospects. *FASEB Journal* (2005) Vol. 19, pp 311-330.
(IF = 5.5, Cit = 1942)

2004

I. Kiran, J. R. Hanson and **A. C. Hunter**. The microbiological hydroxylation of some methoxysteroids by *Cephalosporium aphidicola*. **Journal of Chemical Research-S** (2004) Vol. 5, pp 362-363. (IF = 0.6, Cit = 10)

S. M. Moghimi, **A. C. Hunter**, C. M. Dadswell, S. Savey, C. R. Alving and J. Szebeni. Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)- induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated levels of lipoproteins **Biochimica et Biophysica Acta. Molecular Basis of Disease** (2004) Vol. 1689, pp 103-113.
(IF = 5.1, Cit = 118)

S. M. Moghimi, **A. C. Hunter**, A. Szewczyk and J. C. Murray. Letter-Cellular distribution of non-ionic micelles. **Science** (2004) Vol. 303, pp 626-627.
(IF = 37.2, Cit = 50)

2003

A. C. Hunter and N. E. Carragher Flexibility of the endogenous progesterone lactonisation pathway in *Aspergillus tamaritii* KITA: transformation of a series of cortical steroid analogues. **Journal of Steroid Biochemistry and Molecular Biology** (2003) Vol. 87, pp 301-308.
(IF = 4.5, Cit = 40)

K. D. Pavey, **A. C. Hunter** and F. Paul. Cryogenic surface chemistry observations utilising quartz crystal resonant (QCRS) technology. **Biosensors and Bioelectronics** (2003) Vol. 18, pp 1349-1354. (IF = 8.1, Cit = 6)

J. R. Hanson and **A. C. Hunter**. The microbiological hydroxylation of 3 alpha, 17 beta- and 3 beta, 17 alpha-dihydroxy-5alpha-androstanes by *Cephalosporium aphidicola*. **Journal of Chemical Research-S** (2003) (4): pp 216-217.
(IF = 0.6, Cit = 8)

S. M. Moghimi, K. D. Pavey and **A. C. Hunter**. Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908. **FEBS Letters** (2003) Vol. 547, pp 177-182. (IF = 4.5, Cit = 44)

A. C. Hunter and S. M. Moghimi. Synthetic Polymers in 21st Century Therapeutics **Drug Discovery Today** (2003) Vol. 8, No. 4, pp 154-156.
(IF = 6.3, Cit = 5)

2002

J. K. Gabdamosi, **A. C. Hunter** and S. M. Moghimi. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. **FEBS Letters** (2002) Vol. 523, pp 338-344.
(IF = 4.5, Cit = 151)

A. C. Hunter and S. M. Moghimi. Synthetic polymers: a game of Russian Roulette? **Drug Discovery Today** (2002) Vol. 7, No. 19, pp 998-1001 (Invited Review).
(IF = 6.3, Cit = 108)

G. M. Dick, **A. C. Hunter** and K. M. Saunders. Ethylbromide tamoxifen, a membrane impermeant antiestrogen, activates smooth muscle BK channels from the extracellular side. **Molecular Pharmacology** (2002) Vol 61, No.5, pp 1105-1113.
(IF = 3.9, Cit = 46)

A. C. Hunter, J. Sezbeni, C. R. Alving and S. M. Moghimi. Determination of human serum complement activation by commercial, clinical and chemically modified block copolymer poloxamer 188. **Polymer Preprints** (2002) Vol 43, No.2, pp 739-740.
(Cit =1)

S. M. Moghimi, K. D. Pavey and **A. C. Hunter**. Further evidence in support of *in vivo* surface-modification of nanoparticles by poloxamine 908: Towards generation of long circulating particulate entities. **Polymer Preprints** (2002) Vol 43, No.2, pp 679-680.

2001

S. M. Moghimi and **A. C. Hunter**. Capture of stealth nanoparticles by the body's defences. **Critical Reviews in Therapeutic Drug Carrier Systems** (2001) 18 (6) pp 527-550 (Invited review).
(IF = 6.6, Cit = 154)

S. M. Moghimi, **A. C. Hunter** and J. C. Murray. Long-circulating and target-specific nanoparticles: theory to practice. **Pharmacological Reviews** (2001) Vol 53, No 2, pp 283-318 (Invited review).
(IF = 17.0, Cit = 3690)

M. Sahebgharani, S. P. Hardy, A. W. Lloyd, **A. C. Hunter**, M. C. Allen. Volume-activated chloride channels in HeLa cells are blocked by Tamoxifen but not by a membrane impermeant quaternary analogue. **Cellular Physiology and Biochemistry** (2001) Vol 11, (2) pp 99-104.
(IF = 5.5, Cit = 13)

S. M. Moghimi and **A. C. Hunter** Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. **Pharmaceutical Research (NY)**. (2001) Vol 18, (1), pp 1-8.
(IF = 3.3, Cit = 143)

2000

M. C. Allen, P. A. Gale, **A. C. Hunter** A. Lloyd and S. P. Hardy. Membrane impermeant antioestrogens discriminate between ligand- and voltage-gated cation channels in NG108-15. **Biochimica et Biophysica Acta. Biomembranes**, (2000) 1509, pp 229-236.
(IF = 3.4, Cit = 11)

S. M. Moghimi and **A. C. Hunter**. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. **Trends in Biotechnology**, (2000) 18, No 10, pp 412-420.
(IF = 9.69, Cit = 382)

1998

J. R. Hanson and **A. C. Hunter**. The microbiological hydroxylation of some steroids with a cortical side chain by *Cephalosporium aphidicola*. **Phytochemistry**, (1998) Vol 49. No. 8. pp 2359-2362.

(IF = 3.1, Cit = 8)

C. M. Bensasson, J. R. Hanson and **A. C. Hunter**. The hydroxylation of Δ^5 -androstanes by *Cephalosporium aphidicola*. **Phytochemistry**, (1998) Vol 49. No. 8. pp 2355-2358.

(IF = 3.1, Cit = 28)

J. R. Hanson and **A. C. Hunter**. The hydroxylation of steroidal ring-D lactones by *Cephalosporium aphidicola*. **Phytochemistry**, (1998) Vol 49. No. 8. pp 2349-2353.

(IF = 3.1, Cit = 17)

J.J. R. Hanson, P. B. Hitchcock and **A. C. Hunter**. The microbiological hydroxylation of 3,16-disubstituted androstanes by *Cephalosporium aphidicola*. **Phytochemistry**, (1998) Vol 49. No. 5. pp 1287-1292.

(IF = 3.1, Cit = 12)

J. R. Hanson, **A. C. Hunter** and S. Roquier. The preparation of some 13 α -methyl androstanes **Collection of Czechoslovakian Chemical Communications**, (1998) Vol 63. pp 1646-1654.

(IF = 2.9, Cit = 6)

1997

J. Boynton, J. R. Hanson and **A. C. Hunter**. The hydroxylation of some 13 α -methyl steroids by *Cephalosporium aphidicola*. **Phytochemistry**, (1997) Vol 45. No. 5. pp 951-956.

(IF = 3.1, Cit = 21)

Editorials:

S. M. Moghimi, I. Hamad, and **A. C. Hunter** (2007) Particle nanomedicine in the footsteps of platelet homing. **Nanomedicine**, Vol 2, pp 381-384.

S. M. Moghimi, J.C.Murray and **A. C. Hunter** (2004) Cancer Nanomedicines: Can they deliver their promises? **Scripts**. Vol. 30, pp 16-17.

A. W. Lloyd and **A. C. Hunter**. Monitor: progress and profiles (2000). **Pharmaceutical Science and Technology Today**. Vol. 3, No. 9. pp 327-330; Vol. 3, No. 8. pp 292-294; Vol. 3, No. 7. pp 257-260; Vol. 3, No. 6. pp 210-213; Vol. 3, No. 5. pp 182-183; Vol. 3, No. 4. pp 146-150; Vol. 3, No. 3. pp 106-110; Vol. 3, No. 2. pp 70-74; Vol. 3, No. 1. pp 42-45.

A. W. Lloyd and **A. C. Hunter**. Monitor: progress and profiles (1999). **Pharmaceutical Science and Technology Today**. Vol. 2, No. 12. pp 493-495; Vol. 2, No. 11. pp 457-459; Vol. 2, No. 10. pp 414-417; Vol. 2, No. 9. pp 381-383; Vol. 2, No. 8. pp 340-342; Vol. 2, No. 7. pp 299-302; Vol. 2, No. 6. pp 256-259; Vol. 2, No. 5. pp 213-216; Vol. 2, No. 4. pp 171-173.

Meeting Reports:

A. C. Hunter Natural Products and Medicinal Chemistry-22nd Mona Symposium **IDrugs** (2008) Vol 11, No 3 169-170

A. C. Hunter. Blood Hot in Boston. **Drug Discovery Today**. (2002) Vol. 7, No.21, pp 1082-1084

A. C. Hunter. Surf's up at the new millennium. *Pharmaceutical Science and Technology Today*. (2000) Vol.3, No.9. pp 300-302.

A.W.Lloyd, **A. C. Hunter** and A. Smith. AAPS triggers quest for magic bullet. *Pharmaceutical Science and Technology Today*, (2000) Vol. 3, No. 3. pp 118-120

Peer Reviewed Abstracts:

M. Bahman, Mark Wareing, **A. C. Hunter**, Lynda Harris, (2017) Placental-homing peptides attached to liquid crystal nanoparticles for selective targeting of the placenta. *Placenta*, Vol. 57, pp 252-253.

A.Gallas, **A. C. Hunter**, (2017) Protein composition of systemic sclerosis-related calcinotic deposits. *Rheumatology*, Suppl. 2 Vol. 56.

S. M. Moghimi, **A. C. Hunter**, (2011) Molecular mechanisms of complement attack on block copolymer coated long circulating nanoparticles. *Clinical Biochemistry* Suppl. 2 Vol. 44, S17-S17.

S. M. Moghimi, P. Symonds, **A. C. Hunter**, and J. C. Murray (2006) The molecular basis of immediate and delayed polycation/polyamine-induced cytotoxicity in gene transfer. *Toxicology* Vol. 219, 234-235.

S. M. Moghimi, P. Symonds, , **A. C. Hunter**, G. Debska , A. Szewczyk (2004) Mitochondrial-mediated apoptosis is induced by cationic polymers used in gene transfer. *European Journal of Cancer* Suppl. Vol.2, No. 8, p185.

S. M. Moghimi, P. Symonds, J. C. Murray, **A. C. Hunter**, G. Debska and A. Szewczyk (2004) A two-stage cell death by the cationic macromolecule PEI: Implications in gene transfer and gene therapy. *Revista Cubana de Quimica*. Vol. 16 : A061. ISSN: 0258-5595.

J. Szebeni,, **A. C. Hunter**, C. M. Dadswell, C. R. Alving, S. Savay, S. M. Moghimi (2004) Complement activation by the non-ionic surfactant poloxamer 188 and a regulatory role for HDL and LDL. *Molecular Immunology*. Vol 41 pp 312-313.

J. C. Murray, S. M. Moghimi, **A. C. Hunter**, P. Symonds, G. Debska and A. Szewczyk (2004) Mitochondrial-mediated apoptosis is induced by cationic polymers used in gene transfer. *British Journal of Cancer* Vol. 91 S75-S75 Suppl. 1.

J. Szebeni, C.R. Alving, S. Savay, **A. C. Hunter** and S. M. Moghimi (2001). Variation of complement activation in human serum by Poloxamer 188 (Pluronic-F68). *Proceedings of the International Symposium on Controlled Release of Bioactive Materials*. Abstract Number 5094.

M. C. Allen, P. A. Gale, C. Newland, **A. C. Hunter**, A. W. Lloyd and S. P. Hardy (1999). Inhibition of ligand-gated cation channels by the quaternary ethylbromide derivative of tamoxifen. *Journal of Physiology*. 515.P.

A. C. Hunter, S. T. Meikle, C. Steward and A. W. Lloyd (1999). The synthesis and evaluation of novel anti-bioadherent materials: poly(carboxybetaines). *Journal of Pharmacy and Pharmacology*. 51(S): 318.

A. C. Hunter, E. Ampatzidou, S. Meikle, C. Steward and A. W. Lloyd (1999). The synthesis and evaluation of poly(carboxybetaines) as novel anti-adherent biomaterials. *Artificial Organs*. Vol. 23, No. 7, p.635.

T. A. Paget, A. W. Lloyd, **A. C. Hunter**, R. W. Daisley and E. L. Jarroll (1992). 'Indole-2(3H)-dione derivatives for the treatment of Giardiasis' *Proceedings of the 1st Annual UKaps Conference* (ISBN 0 948917 02 4) p.74.

Referees

Professor S. Moein Moghimi

School of Pharmacy, King George VI Building and Institute of Cellular Medicine,
William Leech Building,
Newcastle University
Newcastle Upon Tyne,
NE2 4HH. UK

Email: seyed.moghimi@ncl.ac.uk

Tel: +44 (0) 191 208 2363

Professor Andrew B. Lowe

Director of Curtin University Nanochemistry Research Institute
Faculty of Science and Engineering,
Department of Chemistry,
Bentley Campus, 500.level 2, 2115
Perth,
Western Australia 6102

Email: Andrew.B.Lowe@curtin.edu.au

Tel: +61 2 92669281

Dr. Peter Taylor (Line Manager)

Associate Professor,

Health and Life Sciences,
Leicester School of Pharmacy,
De Montfort University,
The Gateway,
Leicester, LE1 9BH. UK

E.Mail: pmtaylor@dmu.ac.uk
Tel: +44 (0)116 250 6299